Therefore, this retrospective study comprised 48 patients with HCC or ICC treated with Lenvatinib alone or combined with anti-PD-1, aiming to appraise the efficacy and safety of these treatments in clinical practice in China. The gene discussed is PDCD1; the disease is intrahepatic cholangiocarcinoma.